Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.

Chen X, Liu Y, Yin Y, Jin S, Ping G, Røe OD, Yan K, Shu Y, Guo R.

J Chemother. 2012 Aug;24(4):231-6. doi: 10.1179/1973947812Y.0000000023.

PMID:
23040690
2.

Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites.

Zhao WY, Chen DY, Chen JH, Ji ZN.

Cell Biochem Biophys. 2014 Sep;70(1):623-8. doi: 10.1007/s12013-014-9965-9.

PMID:
24920191
3.

The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.

Chen D, Li X, Zhao H, Fu Y, Yao F, Hu J, Du N.

Indian J Cancer. 2014 Mar;51 Suppl 3:e82-5. doi: 10.4103/0019-509X.154058.

4.

[Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].

Li N, Jin ZL, Liu ZJ, Wang J, Li K.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):937-42. Chinese.

PMID:
22340106
5.

Malignant peritoneal mesothelioma in a child: chemotherapy with gemcitabine and platinum was effective for the disease unresponsive to other treatments.

Kobayashi S, Waragai T, Sano H, Mochizuki K, Akaihata M, Ohara Y, Hosoya M, Kikuta A.

Anticancer Drugs. 2014 Oct;25(9):1102-5. doi: 10.1097/CAD.0000000000000143.

PMID:
25010395
6.

Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice.

Ma X, Yao Y, Yuan D, Liu H, Wang S, Zhou C, Song Y.

PLoS One. 2012;7(12):e53449. doi: 10.1371/journal.pone.0053449. Epub 2012 Dec 28.

7.

Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.

Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME.

Oncology. 2007;73(5-6):426-9. doi: 10.1159/000136800. Epub 2008 Jun 3.

PMID:
18523361
8.

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.

Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M.

Anticancer Drugs. 2012 Feb;23(2):230-8. doi: 10.1097/CAD.0b013e32834d7a1c.

PMID:
22027538
9.

Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.

Habib EE, Fahmy ES.

Clin Transl Oncol. 2013 Nov;15(11):965-8. doi: 10.1007/s12094-013-1015-3. Epub 2013 Feb 14.

PMID:
23408040
10.

Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion.

Fang F, Chen P, Wu X, Yang L, Yang X, Xi ZX, Zhou BW, Zhou XK, Qian ZY, Xiao B, Wei YQ.

J Cancer Res Clin Oncol. 2009 Sep;135(9):1149-57. doi: 10.1007/s00432-009-0555-y. Epub 2009 Feb 15.

PMID:
19219619
11.

[A case of malignant peritoneal mesothelioma treated effectively with cisplatin and gemcitabine].

Tomie A, Okuyama Y, Enoki Y, Tanaka M, Fukui A, Yoshida N, Fujimoto S.

Gan To Kagaku Ryoho. 2010 Oct;37(10):1971-4. Japanese.

PMID:
20948266
12.

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.

Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P.

Lancet Oncol. 2013 May;14(6):543-51. doi: 10.1016/S1470-2045(13)70125-6. Epub 2013 Apr 12.

PMID:
23583604
13.

Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.

Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.

Int J Clin Oncol. 2014 Aug;19(4):601-6. doi: 10.1007/s10147-013-0619-5. Epub 2013 Oct 26.

PMID:
24158772
14.

Pemetrexed combined with platinum-based chemotherapy for advanced malignant peritoneal mesothelioma: retrospective analysis of six cases.

Nakano M, Kusaba H, Makiyama A, Ariyama H, Arita S, Oda H, Esaki T, Takayoshi K, Uchino K, Tamura S, Kumagai H, Iwama E, Shirakawa T, Mitsugi K, Takaishi S, Akashi K, Baba E.

Anticancer Res. 2014 Jan;34(1):215-20.

PMID:
24403465
15.

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.

van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP.

Br J Cancer. 2002 Feb 1;86(3):342-5.

17.

Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).

Pinto C, Marino A, De Pangher Manzini V, Benedetti G, Galetta D, Mazzanti P, Del Conte G, dell'Amore D, Piana E, Giaquinta S, Lopez M, Martoni A.

Lung Cancer. 2006 May;52(2):199-206. Epub 2006 Mar 20.

PMID:
16542747
18.

Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.

Zhang FL, Gao EY, Shu RB, Wang H, Zhang Y, Sun P, Li M, Tang W, Jiang BQ, Chen SQ, Cui FB.

Asian Pac J Cancer Prev. 2015;16(15):6765-8.

19.

Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.

Du N, Li X, Li F, Zhao H, Fan Z, Ma J, Fu Y, Kang H.

Oncol Rep. 2013 Jun;29(6):2332-40. doi: 10.3892/or.2013.2349. Epub 2013 Mar 15.

PMID:
23525453
20.

Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer.

Rong B, Yang S, Li W, Zhang W, Ming Z.

World J Surg Oncol. 2012 Aug 24;10:170. doi: 10.1186/1477-7819-10-170. Review.

Supplemental Content

Support Center